Here’s Why Jacob Funds Established a Position in Cabaletta Bio (CABA)

Group 1: Market Overview - Jacob Funds reported a slight correction in equity markets during November despite robust economic growth throughout the year, with recent conflicting data on consumer spending and the labor market raising doubts about future projections [1] - The firm noted that the recent moderation in AI tech companies could be beneficial, potentially accelerating profit margins and earnings growth while leading to weaker labor markets [1] Group 2: Investment Strategy - Small companies may benefit from the current trends, which could lead to an expansion in valuation multiples, making them favorable for Jacob Funds compared to peers [1] - The investor letter highlighted the top five holdings of the fund, indicating its best picks for 2025 [1] Group 3: Company Spotlight - Cabaletta Bio, Inc. - Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases, with a market capitalization of $284.945 million [2] - The stock closed at $2.96 per share on February 17, 2026, with a one-month return of 26.50% and a twelve-month increase of 37.67% [2] - Jacob Funds added Cabaletta Bio, Inc. to its portfolio, emphasizing its CAR-T-based immunotherapy platform aimed at autoimmune diseases, which shows promising early data for various conditions [3] - The company’s therapy involves using a patient's own blood, treating it, and reinfusing it to reset the immune system, with safety and durability being critical for success [3] - Upcoming data releases in the next 12 months are expected to validate the treatment's viability, and the ongoing clinical studies are designed to avoid arduous preconditioning processes for patients [3]